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The mitochondrial negative regulator MCJ is a
therapeutic target for acetaminophen-induced liver
injury
Lucía Barbier-Torres1, Paula Iruzubieta1,2, David Fernández-Ramos1, Teresa C. Delgado1, Daniel Taibo1,
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Acetaminophen (APAP) is the active component of many medications used to treat pain and
fever worldwide. Its overuse provokes liver injury and it is the second most common cause of
liver failure. Mitochondrial dysfunction contributes to APAP-induced liver injury but the
mechanism by which APAP causes hepatocyte toxicity is not completely understood.
Therefore, we lack efficient therapeutic strategies to treat this pathology. Here we show that
APAP interferes with the formation of mitochondrial respiratory supercomplexes via the
mitochondrial negative regulator MCJ, and leads to decreased production of ATP and
increased generation of ROS. In vivo treatment with an inhibitor of MCJ expression protects
liver from acetaminophen-induced liver injury at a time when N-acetylcysteine, the standard
therapy, has no efficacy. We also show elevated levels of MCJ in the liver of patients with
acetaminophen overdose. We suggest that MCJ may represent a therapeutic target to
prevent and rescue liver injury caused by acetaminophen.
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Acetaminophen, also called APAP (from acetyl-para-ami-nophenol), is the active component of many commonlyprescribed and over-the-counter medications used to treat
pain and fever worldwide. It is estimated that over 60 million
people within the United States consume APAP weekly. APAP is
known to be a safe analgesic drug, but it is also the principal cause
of acute liver failure (ALF) in the US and Europe1. While the first
evidence that APAP could cause hepatotoxicity were described
over 50 years ago, it was not until 2014 when the FDA (USA Food
and Drug Administration) recognized its overuse as a major
health problem, revised their previous approval, and limited its
consumption to no more than 4000 mg per day. This dose is
usually safe, although there are factors (e.g., alcohol, chronic liver
diseases, nutrition, age, genetics) that can affect the maximum
tolerated dose of APAP and it is becoming more evident that
some patients also develop acute liver injury with lower doses2.
About 30,000 patients per year are admitted to intensive care
units with APAP-induced liver injury3 and close to 29% of
patients with APAP-induced ALF undergo liver transplantation4.
The timing from APAP ingestion to hospitalization is critical.
Within 4 h of ingestion, physical removal of APAP from the
gastrointestinal tract is usually effective. Treatment with the
antioxidant, N-acetylcysteine (NAC), is the standard therapy
upon hospitalization and it is recommended to be given as an
antidote even before the diagnosis is confirmed5. NAC to treat
APAP-induced liver injury is effective at 8 h after ingestion.
However, with time NAC has a lower chance of rescuing the liver,
therefore other alternative approaches are needed6.
The mechanisms underlying APAP-induced acute liver injury
are not fully understood although mitochondria dysfunction
plays a pivotal role. While most APAP metabolites are easily
eliminated through the urine, N-acetyl-para-benzoquinone imine
(NAPQI) is a highly reactive metabolite that increases oxidative
stress and causes a severe impairment in mitochondrial function
leading to a profound depletion of ATP and the activation of the
stress kinase, c-Jun N-terminal (JNK)7. ATP produced in mito-
chondria is generated through the electron transport chain
(ETC), which is formed by multi-subunit complexes (complexes
I, II, III, and IV) that feed into complex V-ATP synthase. ETC
complexes associate into mitochondrial respiratory super-
complexes, formed by complex I, III, and IV, displaying enhanced
complex I activity with lower risk of electron leak and production
of reactive oxygen species (ROS)8, 9. Overdoses of APAP have
been reported to modulate complex I and complex II activities in
rat hepatocytes in vitro10 and in vivo11 leading to increased
oxidative stress and reduction in ATP production10–12. These two
outcomes seem to be the main cause of hepatocyte necrosis. Thus,
sustaining mitochondrial respiration while preventing oxidative
stress could be a potential therapeutic approach to overcome
APAP-induced liver injury.
A number of molecules that are not intrinsic components of
ETC complexes have been found to positively contribute to the
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Fig. 1 MCJ expression determines the susceptibility of hepatocytes to APAP toxicity. a, b Cell death in WT and MCJ KO hepatocytes using TUNEL assay
(a) and Trypan blue staining (b) after treatment with APAP for 9 and 6 h, respectively. c JNK activation was evaluated by western blotting in WT and MCJ
KO hepatocytes after APAP exposure. d, e Cell death in MCJ KO hepatocytes and MCJ KO hepatocytes transfected with MCJ (MCJ KO-MCJ) using
TUNEL assay (d) and Trypan blue staining (e) after treatment with APAP for 9 and 6 h, respectively. f, g Cell death in WT hepatocytes and WT
hepatocytes transfected with siMCJ (siMCJ) using TUNEL assay (f) and Trypan blue staining (g) after treatment with APAP for 9 and 6 h, respectively. h–j
Mitochondrial ROS in WT and MCJ KO hepatocytes (h), MCJ KO hepatocytes, and MCJ KO hepatocytes transfected with MCJ (i), WT hepatocytes, and
WT hepatocytes transfected with siMCJ (j) MCJ KO-MCJ upon 6 h of APAP treatment using MitoSOX staining. Values are represented as mean± SEM.
*P< 0.05 (Student’s t test) (MCJ KO vs. WT, MCJ KO-MCJ vs. MCJ KO, and siMCJ vs. WT). Triplicates were used for experimental condition
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activity of complex I (e.g., STAT3, Rcf1, GRIM-19), and depletion
or inhibition of these co-activators results in decrease ETC
activity13–15. In contrast, MCJ (also called DnaJC15) is an
endogenous negative regulator of complex I that has been
recently identified16. MCJ is a transmembrane protein that
localizes in the inner membrane of the mitochondria16, 17. MCJ
interacts with complex I to decrease its activity in part by inter-
fering with the formation of respiratory supercomplexes16. MCJ is
abundantly expressed in specific tissues including the heart, liver,
kidney, and within the immune system, in macrophages and CD8
lymphocytes18, 19. Importantly, the absence of MCJ has been
shown to enhance complex I activity, mitochondrial membrane
potential, and mitochondrial respiration, although it does not
increase mitochondrial ROS, due to the enhanced formation of
supercomplexes19. Under physiological conditions, MCJ defi-
ciency in mice does not cause an altered phenotype16. However,
in conditions that lead to an overaccumulation of fat in the liver,
MCJ deficiency prevents such accumulation16, suggesting that
MCJ may also act as a brake of mitochondrial respiration in the
liver, and could therefore modulate APAP-induced drug injury.
In this study, we show that APAP-induced liver injury pro-
gresses through the central participation of MCJ in vitro and
in vivo. The repression of MCJ expression prevents APAP-
mediated inhibition of mitochondrial complex I activity and ATP
production, as well as APAP-induced oxidative stress in hepa-
tocytes by sustaining the formation of supercomplexes. These
mechanisms lead to reduction in liver damage triggered by APAP
as well as increased liver regeneration capacity by targeting MCJ
levels. Moreover, we show higher levels of MCJ in livers from
patients admitted with life-threating overdoses of APAP relative
to healthy individuals. Thus, MCJ emerges as a novel druggable
target for APAP-induced liver injury.
Results
Loss of MCJ protects hepatocytes from APAP-induced toxicity.
To investigate whether MCJ could modulate APAP-induced liver
damage, we isolated primary hepatocytes from wild type (WT)
and MCJ knockout (KO) mice and treated them with APAP.
Within 9 h of treatment, marked toxicity features were observed
in WT primary hepatocytes, but hepatocytes from MCJ KO mice
were significantly protected, as assessed by TUNEL assay (Fig. 1a)
and Trypan blue staining (Fig. 1b). In correlation, minimal
phosphorylation of JNK was detected in MCJ KO hepatocytes
upon APAP treatment compared with WT hepatocytes (Fig. 1c).
We then restored MCJ expression in MCJ KO hepatocytes with a
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Fig. 2MCJ deletion protects against APAP hepatotoxicity in vivo. WT (n= 6) and MCJ KO mice (n= 6) were treated with APAP 360mg/kg for 48 h. Liver
damage was evaluated by a hematoxylin and eosin (H&E) and b TUNEL staining in liver sections. c, d Serum alanine aminotransferase (ALT) levels in WT
and MCJ KO fed animals (c) and starved animals at 24 h after APAP (d). e Inflammation assessed by F4/80 staining in liver. f Total GSH levels measured
by HPLC-MS in WT and MCJ KO livers after 6 h of APAP treatment (n= 5). g GSSG/GSH levels measured by HPLC-MS in WT and MCJ KO livers. h JNK
activation by western blotting in WT and MCJ KO liver extracts after 1 h of APAP treatment (n= 5). i ROS in vivo measured by dihydroethidium (DHE)
staining in liver sections. Scale bar corresponds to 100 μm. Values are represented as mean± SEM. *P< 0.05 (Student’s t test) (MCJ KO vs. WT)
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MCJ-expressing construct (Supplementary Fig. 1a) and examined
APAP responses. Ectopic expression of MCJ rescued the sensi-
tivity of MCJ KO hepatocytes to APAP-induced cell death
(Fig. 1d, e). In addition, the transient repression of MCJ
expression in WT hepatocytes with an siRNA (siMCJ), to reduce
the levels of MCJ (Supplementary Fig. 1b), decreased death
caused by APAP treatment (Fig. 1f, g). Together, these data show
that loss of MCJ confers resistance to APAP-mediated toxicity in
hepatocytes in vitro. The production of mitochondrial ROS
triggered by APAP is a mechanism by which APAP causes cell
death in the liver7. We examined the production of mitochondrial
ROS in WT and MCJ KO hepatocytes upon treatment with
APAP by MitoSOX staining and found high levels of ROS in WT
hepatocytes but not in MCJ KO hepatocytes (Fig. 1h). Production
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of mitochondrial ROS in MCJ KO hepatocytes triggered by APAP
was restored upon ectopic expression of MCJ (Fig. 1i). In addi-
tion, decreasing the levels of MCJ in WT hepatocytes by trans-
fection of siMCJ also reduced ROS production triggered by APAP
(Fig. 1j). Thus, disrupting MCJ expression markedly reduces the
production of ROS and cell death caused by APAP in hepatocytes
in vitro.
Loss of MCJ protects from APAP-induced liver injury in vivo.
MCJ levels were assessed in the mouse model of APAP-induced
liver injury, and its expression was significantly increased at
protein levels, without changes in mRNA levels (Supplementary
Fig. 2a, b). Therefore, to determine the role of MCJ, WT, mice
and MCJ KO mice were administered with 360 mg/kg of APAP
frequently used to mimic the ALF caused by this compound.
After 48 h, the mice were sacrificed and tested for a number of
markers of liver damage. Histological analysis demonstrated an
abundant presence of necrotic areas in the liver of WT mice
administered APAP while the livers from MCJ KO mice
remained predominantly unaffected (Fig. 2a). Protection of liver
tissue damage in MCJ KO mice was further determined by the
lower frequency of cell death assayed by TUNEL (Fig. 2b).
Analysis of alanine transaminase (ALT, commonly used in the
clinic to diagnose APAP-induced liver injury) levels in serum
revealed marked lower levels in MCJ KO mice at early (6 h) as
well as late (24 and 48 h) time points after APAP administration
(Fig. 2c). It is known that starvation of mice markedly increases
serum levels of transaminases, similar to what is observed in
patients. However, despite the extremely high levels of ALT in
WT mice that were fasted overnight and treated with APAP, these
levels were drastically reduced in MCJ KO mice (Fig. 2d). Liver
inflammation, a result of hepatocyte cell death, was also sig-
nificantly reduced in MCJ KO mice compared with WT mice as
determined by the presence of F4/80 positive cells after 48 h of
APAP administration (macrophages) (Fig. 2e). Thus, the absence
of MCJ protects hepatocytes from APAP-induced injury in vivo.
In order to discard possible alterations in APAP metabolism
between WT and MCJ KO mice, NAPQI-GSH and total
glutathione levels were assessed in WT and MCJ KO livers 6 h
after APAP injection. Total levels of glutathione were not
different (Fig. 2f). In addition, we also examined GSSG/GSH
ratios in the livers of WT and MCJ KO mice at different times
after APAP administration. GSSG/GSH ratios were lower in MCJ
KO mice even early after APAP administration, suggesting a
reduced index of oxidative stress in the absence of MCJ (Fig. 2g).
Reduced levels of activated JNK after 1 h of APAP administration
in MCJ KO mice correlated with the reduced oxidative stress
(Fig. 2h). Furthermore, analysis of ROS measured by dihy-
droethidium (DHE) staining in liver sections at 6 (Supplementary
Fig. 3) and 48 h (Fig. 2i) after APAP administration showed
minimal levels in MCJ KO mice relative to WT mice. Thus, MCJ
KO mice are protected from liver oxidative stress and injury
triggered by APAP.
MCJ siRNA treatment after APAP administration overcomes
liver damage. The use of siRNA attenuates expression of liver
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genes in animals as well as in humans, and it is being used as
therapeutics in a number of clinical trials for liver diseases20–22.
To assess whether MCJ could be used as a potential target to treat
APAP-induced liver damage we examined the effect of a MCJ-
specific siRNA (siMCJ). WT mice were administered with APAP
and received a single dose i.v. of siMCJ 6 h later, when liver
transaminases are already altered (Fig. 2c). After 48 h of APAP
administration, mice were sacrificed and MCJ expression in the
liver was determined by immunoblot. The levels of MCJ were
drastically reduced by siMCJ treatment (Fig. 3a). Analysis of
APAP-induced liver damage by histology showed minimal
necrotic areas in livers from mice treated with siMCJ relative to
controls (Fig. 3b). The major reduction in liver damage after
treatment with siMCJ was further demonstrated by the presence
of minimal oxidative stress as determined by DHE staining of
liver sections (Fig. 3c). Analysis of inflammation in the liver
showed lower number of macrophages in the liver in mice treated
with siMCJ (Fig. 3d). Decreased inflammation in the liver of
siMCJ-treated mice was further supported by lower mRNA levels
of inflammatory cytokines (e.g., IL-6 and IL-1β), chemokines, and
chemokine receptors (e.g., CCL5, CCR5) (Fig. 3e). Importantly,
the analysis of serum transaminases revealed that the treatment
with siMCJ restored ALT and AST levels to normal (Fig. 3f).
Together these results show that inhibiting MCJ expression after
6 h of a toxic APAP administration can reverse tissue damage.
NAC is the sole available therapy for treatment of the APAP
overdose patients, but when administered after 8 h upon APAP
uptake its efficiency diminishes drastically. To compare the
beneficial effect of NAC vs. siMCJ, WT mice were administered
with APAP and treated with NAC 6 h later and hepatoxicity was
examined 48 h after administration of APAP. In contrast to
siMCJ treatment, liver damage determined by histology (Supple-
mentary Fig. 4a), serum ALT (Supplementary Fig. 4b), and liver
inflammation (Supplementary Fig. 4c) was not affected by the
treatment with NAC. As a control for NAC activity, additional
experiments were performed where treatment with NAC was
provided 1 h after APAP administration. In contrast to the 6 h
post-APAP treatment, NAC treatment after 1 h attenuated liver
damage (Supplementary Fig. 4d) and restored serum ALT levels
to normal (Supplementary Fig. 4e). In addition, analysis of liver
oxidative stress caused by APAP was only restored if NAC was
provided 1 h after the administration of APAP, but not after 6 h
(Supplementary Fig. 4f). These data suggest that siMCJ treatment
has superior efficacy than NAC at 6 h post-APAP treatment.
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To further demonstrate the superior therapeutic effect of siMCJ
we also examined the efficacy of siMCJ when provided 24 h after
the administration of APAP when damage in liver was clearly
detectable. Hepatotoxicity was examined 48 h after APAP
administration. At this longer time point, the levels of MCJ were
also drastically reduced by siMCJ treatment (Supplementary
Fig. 5). Interestingly, mice treated with siMCJ presented minimal
signs of liver damage as determined by histological analysis of the
liver (Fig. 3g). Similar to the effect obtained with the treatment
after 6 h, minimal oxidative stress was found in livers from
siMCJ-treated mice after 24 h post APAP (Fig. 3h). Accordingly,
the inflammatory response in siMCJ mice was also reduced
(Fig. 3i). Most importantly, serum ALT levels (Fig. 3j) were also
substantially decreased in siMCJ-treated mice. These data showed
the efficacy of siMCJ as a treatment for APAP-induced liver
injury even 24 h after APAP uptake, making it a potentially more
effective treatment for ALF.
APAP fails to inhibit mitochondrial respiration in the absence
of MCJ. The hepatic cell death induced by APAP is closely related
to cellular ATP depletion. We therefore examined the effect of
APAP on total ATP levels in WT and MCJ KO hepatocytes
in vitro. APAP caused a marked reduction in total ATP levels in
WT hepatocytes, but had a minimal effect in MCJ KO hepato-
cytes (Fig. 4a). ATP can be synthesized through glycolysis in the
cytosol or through oxidative phosphorylation (OXPHOS) in
mitochondria. MCJ is a negative regulator of mitochondrial ATP
synthesis by OXPHOS16. We investigated whether APAP has an
effect on mitochondrial respiration and whether this effect is
modulated by the absence of MCJ. APAP caused a pronounced
decrease in the basal oxygen consumption rate (OCR) in WT
hepatocytes (Fig. 4b). In contrast, OCR remained high in the
presence of APAP in MCJ KO hepatocytes (Fig. 4b). Thus, loss of
MCJ prevents APAP-mediated inhibition of cell respiration as
determined by oxygen consumption.
We then investigated the effect of APAP on mitochondrial
ATP production rate. APAP lowered the production of
mitochondrial ATP in WT hepatocytes, but had no effect on
mitochondrial ATP production in MCJ KO hepatocytes in vitro
(Fig. 4c). We also examined whether the absence of MCJ
prevented ATP depletion by APAP in vivo. WT and MCJ KO
mice were administered with APAP or vehicle and after 24 h
mitochondria were purified from livers and ATP levels in liver
mitochondrial extracts were examined. APAP caused a reduction
in mitochondrial ATP levels in WT mice, but had no effect in
MCJ KO mice (Fig. 4d). Thus, the absence of MCJ prevents
mitochondrial ATP depletion triggered by APAP in the liver both
in vitro and in vivo.
Increased levels of ATP in the liver after injury could facilitate
liver regeneration, an energetically demanding process23. Thus,
the sustained levels of ATP found in siMCJ-treated mice could
help the regenerative response during the late phases of APAP-
induced liver injury. We therefore treated mice with siMCJ 24 h
after APAP administration and examined livers 12 h later. The
levels of MCJ were reduced upon siMCJ treatment as determined
by western blot analysis (Fig. 4e). Histological analysis confirmed
the beneficial effect of siMCJ by the reduction of liver damage as
determined by necrotic areas (Fig. 4f). Importantly, analysis of
PCNA immunostaining in liver sections as a marker for
hepatocyte proliferation during liver regeneration showed
increased stained cells in siMCJ-treated mice (Fig. 4g). Thus,
silencing of MCJ at late phases of APAP toxicity increased the
regenerative capacity of the livers. This effect could explain the
superior effect of siMCJ relative to NAC when provided later after
APAP administration.
Loss of MCJ prevents APAP interferences in supercomplexes
formation. Loss of MCJ has been shown to increase mitochon-
drial complex I activity in the heart and T cells16. To determine
the effect of loss of MCJ in complex I activity in liver in vivo,
mitochondria were isolated from livers of WT and MCJ KO mice,
and OCR in isolated mitochondria was examined using substrates
for complex I (glutamate and malate). Complex I-mediated OCR
was higher in mitochondria from MCJ KO livers (Fig. 5a),
showing that MCJ also acts as a negative regulator of complex I in
this organ. We then examined complex I-mediated OCR in
mitochondria isolated from livers of WT and MCJ KO mice that
were administered APAP 1 h before in vivo. Complex I activity
remained higher in APAP-administered MCJ KO mice compared
to WT mice (Fig. 5b).
While complex I activity is the key for mitochondrial ATP
production, increased complex I activity and mitochondrial
membrane potential is often associated with increased production
of mitochondrial ROS due to electron leak24. However, despite
the increased complex I activity, our data (Fig. 1h) show
decreased mitochondrial ROS production triggered by APAP in
MCJ KO hepatocytes relative to WT hepatocytes. Moreover,
complex I activity contributes to the generation of ROS in WT
hepatocytes in response to APAP since treatment with rotenone,
an inhibitor of complex I, decreased ROS levels (Fig. 5c). Thus,
MCJ deficiency in hepatocytes sustains complex I activity while
minimizing the production of ROS in response to APAP.
Complex I associates with complex III and IV of the ETC to
form respiratory supercomplexes or “respirasomes”8, facilitating
the efficient transfer of electrons and minimizing the risk of
electron “leakage” and thereby ROS production while increasing
complex I activity15, 25, 26. We investigated whether APAP could
affect supercomplex formation in hepatocytes. Mitochondrial
extracts were prepared from WT and MCJ KO hepatocytes
untreated or treated with APAP and resolved by blue native
electrophoresis (BNE) followed by western blot analysis for the
complex I subunit, NDUFA9. The levels of NDUFA9 present in
the supercomplex region were substantially lower in WT
hepatocytes treated with APAP compared to untreated cells
(Fig. 5d). In contrast, APAP treatment had no effect in
supercomplex levels in MCJ KO hepatocytes (Fig. 5d). The levels
of NDUFA9 present in the monomeric complex I region were
comparable in both WT and MCJ KO cells independently of
APAP treatment (Fig. 5d), indicating that APAP selectively
interferes with the formation of supercomplexes. We also
investigated the effect of APAP in the formation of super-
complexes in the liver in vivo. WT and MCJ KO mice were
administered with APAP and after 6 h mitochondrial liver
extracts were generated and resolved as above. Similar to the
results in vitro, APAP markedly decreased liver supercomplex
levels in WT mice, but had no effect in MCJ KO mice (Fig. 5e).
Thus, APAP interferes with the formation of supercomplexes in
liver both in vitro and in vivo, and the absence of MCJ protects
from this inhibitory effect.
To demonstrate that the resistance of MCJ-deficient hepato-
cytes to APAP-induced toxicity occurs through increased
complex I activity, we performed TUNEL assays after treatment
of WT and MCJ KO hepatocytes with APAP in the absence or
presence of rotenone, an inhibitor of complex I. As shown above,
minimal cell death was detected in MCJ KO hepatocytes treated
with APAP, but the combination of APAP and rotenone
significantly increased cell death (Fig. 5f). In contrast, rotenone
failed to further increase cell death over that caused by APAP
alone in WT hepatocytes (Fig. 5f). Thus, the protective effect
against APAP-mediated toxicity in the absence of MCJ is due to
increased complex I activity, associated with a decrease in ROS
because of sustained supercomplex formation.
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Elevated hepatic MCJ levels in acetaminophen overdose
patients. To investigate whether MCJ could also be associated
with susceptibility to liver toxicity in humans, we measured the
expression of MCJ in liver biopsies from healthy individuals and
patients diagnosed with drug-induced liver injury as described in
Table 1. MCJ expression was assayed by immunohistochemistry
analysis in tissue sections (Fig. 6a). Quantitative analysis showed
significantly higher MCJ levels in the liver from DILI patients
relative to healthy controls (Fig. 6b). Furthermore, drugs were
classified according to their known mitochondrial hazards based
on published information27, 28. Interestingly, highest levels of
MCJ in liver were found in patients with DILI caused by drugs
hazardous for mitochondria (Fig. 6c). These data reveal a corre-
lation between MCJ levels in the liver and liver injury caused
specifically by mitochondrial dysfunction-inducing hepatotoxic
drugs.
To further demonstrate a functional link between the presence
of MCJ in the liver and acetaminophen-induced liver toxicity in
humans, we measured the expression of MCJ in 21 liver biopsies
from liver failure causes transplantations resulting from acet-
aminophen overdose (Fig. 6d). MCJ expression was assayed by
immunohistochemistry analysis in tissue sections. Quantitative
analysis showed significantly higher MCJ levels in the liver from
ALF patients relative to healthy controls (Fig. 6e). These data
reveal a correlation between MCJ levels in the liver and life-
threating liver injury in patients after acetaminophen abuse.
Discussion
Drug-induced liver injury caused most commonly by acet-
aminophen is a major cause of liver pathology. Indeed, APAP
overuse is the most common trigger of ALF in the United States.
If not treated in a short period of time upon the initiation of the
pathology, it requires liver transplantation and in some cases, can
result in death. Understanding the mechanisms by which APAP
causes toxicity is therefore essential to overcome liver damage
with appropriate therapies. Here we show that MCJ regulates
mitochondrial ETC function in the liver, which determines the
Table 1 Characteristics of DILI patients
All patients Hepatocellular injury Cholestatic injury Mixed injury
n 21 9 7 5
Age (years) 49.3± 19.6 49.7± 19 47.7± 18.1 51.8± 26.8
Gender (F/M) 10/11 5/4 3/4 2/3
ALT (U/L) 438.8± 428.7 163.1± 109.5 722.4± 528.8 314.0± 89.8
AST (U/L) 324.9± 393.7 123.7± 58.8 568.2± 514.9 168.4± 70.2
GGT (U/L) 386.5± 433.1 744.5± 646.2 38.9± 35.6 296.2± 268.4
ALP (U/L) 360.8± 419.2 655.6± 617.1 143.2± 72.2 339.8± 194.3
TBIL 7.5± 6.0 6.6± 5.4 8.4± 7.4 7.3± 4.8
Severity, n (%)
Mild 6 (28.6) 3 (33.3) 2 (28.6) 1 (20)
Moderate 11 (52.4) 3 (33.3) 5 (71.4) 3 (60)
Severe 3 (14.3) 2 (22.2) 0 (0) 1 (20)
Fatal 1 (4.8) 1 (11.1) 0 (0) 0 (0)
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma glutamyl transferase, TBIL total bilirubin
Data are expressed as mean± SD
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Fig. 6MCJ expression is increased in human DILI. a–c Human samples from healthy control subjects (Healthy) (n= 7) and from patients with drug-induced
liver injury (DILI) (n= 21). a MCJ expression in liver was determined by immunohistochemistry and b quantified. c Correlation between MCJ expression
and drug grade of mitochondrial liability in DILI patients. d, e Human samples from healthy control subjects (Healthy) (n= 7) and from patients with
acetaminophen-induced liver injury (APAP) (n= 24). a MCJ expression in liver was determined by immunohistochemistry and b quantified. Scale bar
corresponds to 100 μm. Values are represented as mean± SEM. *P< 0.05 (Student’s t test) (DILI vs. Healthy, mitochondrial hazardous vs. non-
mitochondrial hazardous, and APAP vs. Healthy)
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01970-x
8 NATURE COMMUNICATIONS | 8:  2068 |DOI: 10.1038/s41467-017-01970-x |www.nature.com/naturecommunications
pathological features of APAP-induced liver damage in a murine
model. Our data in this model show that reducing the levels of
MCJ in the livers after 24 h of APAP administration prevents liver
injury, demonstrating a superior efficacy over the treatment with
NAC, the only current therapy in the clinical practice for ALF.
These results point to MCJ as a key therapeutic target for the
treatment of this prevalent hepatotoxic condition. Our results
showing significantly higher levels of MCJ in livers from ALF
patients that were under liver transplant due to acetaminophen
overdose support this concept.
Mitochondria are the primary intracellular organelles targeted
by APAP since inhibition of mitochondrial bioenergetics is a very
early event during APAP-induced liver injury11. APAP hepato-
toxicity is a complex process that involves the generation of
mitochondrial oxidant stress, hepatocyte cell death, and regen-
eration at the latest stage. Our results provide a mode of action of
APAP in the generation of oxidative stress. The respiratory
complexes of the ETC in the mitochondria assemble into what are
now known as respiratory supercomplexes or respirasomes. The
formation of these higher order structures bring together complex
I, a complex III dimer, and complex IV facilitating the transport
of electrons, and minimizing electron leakage and the generation
of ROS8, 9. Although initially the presence of supercomplexes in
the inner membrane of mitochondria was questioned, the eluci-
dation of these structures by cryo-electron microscopy has pro-
vided full demonstration27, 28. Our studies show that APAP
disrupts the formation of supercomplexes in hepatocytes in vitro
and in the liver in vivo. Disruption of supercomplexes would lead
to increased production of ROS due to elevated electron leakage
between complex I and III. We show here that in the absence of
MCJ, supercomplexes are refractory to APAP-mediated disrup-
tion in liver mitochondria. Thus, APAP-mediated disaggregation
of mitochondrial supercomplexes is dependent on MCJ. It is
possible that APAP metabolites, including NAPQI, promote the
interaction of MCJ with complex I, thereby interfering with the
association of complex I with III. Augmented levels of MCJ may
therefore predict the increased sensitivity to APAP.
Here we also show that APAP fails to reduce mitochondrial
ATP production in hepatocytes in the absence of MCJ, a negative
regulator of complex I. These results indicate that the inhibitory
effect of APAP on complex I is dependent on MCJ expression,
and that blocking MCJ protects liver from APAP-mediated
injury. In addition to complex I some studies suggest that APAP
also interferes with the activity of complex II, the succinate
dehydrogenase complex. In fact, the APAP metabolite, NAPQI,
inhibits complex II activity. The contribution of complex II to
overall mitochondrial respiration and ATP production is cell type
dependent and it has a major role in hepatocytes29. The extent of
the contribution of APAP metabolites to hepatotoxicity through
inhibition of complex II activity and whether it is modulated by
MCJ remains to be determined.
Overall, our studies reveal a mechanism of APAP-induced liver
injury that involves the mitochondrial ETC inhibitor, MCJ. Cri-
tically, silencing MCJ protects liver from the downstream
pathological injury caused by APAP. Results from a number of
ongoing clinical trials have revealed that siRNA treatment is an
efficient therapeutic approach to target genes in the liver30, 31.
Thus, a similar treatment targeting MCJ may show efficacy for
the treatment of APAP liver damage in those cases where NAC is
proven inefficient. Moreover, silencing MCJ at later time points
(24 h) of APAP administration, once the injury phase is ended,
revealed its role in the regenerative stage of liver damage. Liver
regeneration requires large amounts of energy and previous
experimental evidence suggests that mitochondrial function is of
paramount importance for this process32, 33. Thus, the increase in
energy delivery and ATP production observed in the absence of
MCJ in the liver help explain the high proliferative rate observed
post-APAP treatment at late stages. Therefore, accelerated liver
regeneration by silencing MCJ could decrease morbidity and
mortality of ALF patients.
Since our results show most ALF patients have elevated levels
of MCJ in the liver relative to healthy controls, siMCJ could be
provided as a treatment to any patient who gets admitted into the
ER after acetaminophen overdose, independently of the levels of
MCJ in the liver. Because we have not observed signs of toxicity in
mouse studies, even in the absence of benefit for those individuals
with not elevated MCJ in their livers, no risk of harm would be
expected. The fact that fully MCJ-deficient mice are healthy
further supports minimal toxicity of siMCJ as therapeutic.
Methods
Human samples. A total of 24 samples from patients undergoing urgent liver
transplantations for ALF resulting from acetaminophen overdose were evaluated
for MCJ expression. Sex distribution was similar (11 male, 10 female), with a
median age of 37 (range 15–49). Microscopy after Hematoxylin and Eosin stain
revealed widespread necrosis, particularly in zones 2 and 3, in keeping with acute
acetaminophen injury. Steatosis and hepatocyte ballooning was observed in zone 1
residual hepatocytes in a number of the cases. The diagnosis of ALF was established
in Newcastle Hospitals NHS Foundation Trust (Newcastle, England), Azienda
ospedaliero-universitaria Policlinico di Modena (Modena, Italy), and Hospital
Virgen de la Victoria, (Malaga, Spain) based on clinical data, features of liver
histology, and exclusion of other possible causes of liver injury (viral hepatitis,
biliary diseases, alcohol abuse, non-alcoholic fatty liver disease, autoimmune liver
diseases, and hereditary diseases).
Moreover, a total of 21 samples from patients with drug-induced liver injury
(Hospital Virgen de la Victoria, (Malaga, Spain)) described in Table 1 were
evaluated for MCJ expression.
Healthy human liver samples (n = 4/7) from organ donor patients from
Marqués de Valdecilla University Hospital (Santander, Spain) were used as controls
for immunostaining analyses.
The studies were approved by the Research Ethics Committees of Modena IRB
90/12, IDIVAL Cantabria 2017.052, Malaga Hospital, and Newcastle Biomedicine
Biobank (12/NE/0395), approved by Newcastle Research Ethics Committee North
East Newcastle and North Tyneside.
All patients gave informed consent for all clinical investigations, according to
the principles embodied in the Declaration of Helsinki.
Histology. Paraffin-embedded liver samples were sectioned, dewaxed, and
hydrated. All procedures were performed according to standard protocols using the
EnVision+System HRP (Dako, Denmark). Samples were incubated with Vector
Vip substrate (Vectorlabs, Burlingame, USA) for color development. About 5–10
random images per sample were taken with a ×20 objective from an AXIO Imager
A1 microscope (Carl Zeiss AG, Jena, Germany). Quantification of staining inten-
sity, average sum of intensities, and stained area percentage of each sample were
calculated using FRIDA software (FRamework for Image Dataset Analysis) http://
bui3.win.ad.jhu.edu/frida/.
Determination of ROS in liver tissue sections. Samples were sectioned in a
criostat (8 μms), and incubated with MnTBAP 150 μM at RT during 1 h. The
samples were then incubated with DHE 5 μM for 30 min at 37 °C34. Sections were
mounted with mounting media containing DAPI.
Experimental procedures in animals. MCJ KO mice were previously described15.
MCJ KO mice and WT mice are in the C57Bl/6J background. MCJ KO mice were
backcrossed over 15 times. Both colonies were bred at the CIC bioGUNE animal
facility.
Three-month-old male WT and MCJ KO mice were treated with
acetaminophen (APAP, Sigma-Aldrich) by intraperitoneal injection at a dose of
360 mg/kg once. Animals were sacrificed 6, 24, and 48 h after APAP injection.
NAC 1200 mg/kg was administrated by a single 200 μl intraperitoneal injection of a
solution of NAC 150 μg/μl. Animal procedures were approved by the CIC
bioGUNE Animal Care and Use Committee and the local authority (Diputación de
Bizkaia) according to the criteria established by the European Union. Animal
procedures were approved by the University of Vermont Institutional Animal Care
and Use Committee.
In vivo silencing. For MCJ silencing, APAP 360 mg/kg was injected in 3-month-
old WT mice. About 6 and 24 h later, the animals were divided into two groups
(n = 6) and received either 200 μl of a 0.75 μg/μl solution of MCJ-specific siRNA or
control siRNA using Invivofectamine 3.0 Reagent (Thermo Fisher Scientific) by tail
vein injection. Animals were sacrificed at 36 and 48 h after APAP treatment.
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Isolation and culture of primary hepatocytes. Primary hepatocytes from WT
and MCJ KO mice were isolated by perfusion with collagenase type IV (Wor-
thington). In brief, mice were anesthetized with isoflurane (1.5% isoflurane in O2),
the abdomen was opened and a catheter was inserted into the vena. Liver was
perfused with buffer A (1× PBS, 5 mM EGTA) (37 °C, oxygenated) and portal vein
was cut. Subsequently, liver was perfused with buffer B (1× PBS, 1 mM CaCl2,
collagenase type I (Worthington)) (37 °C, oxygenated). After the perfusion, liver
was placed in a Petri dish containing buffer C (1× PBS, 2 mM CaCl2, 0.6% bovine
serum albumin (BSA)) and disaggregated with forceps. Digested liver was filtered
through sterile gauze; hepatocytes were collected and washed twice in buffer C
(300 rpm, 3 min, 4 °C). Supernatant was removed and hepatocytes were resus-
pended in fresh 10% fetal bovine serum (FBS; Gibco) Minimun essential medium
(MEM; Gibco) contains penicillin (100 U/ml), streptomycin (100 U/ml), and glu-
tamine (2 mM) (PSG; Invitrogen). Cell viability was validated by trypan blue
exclusion test and more than 80% of viability was considered for the experiments.
In vitro silencing. WT primary hepatocytes were transfected with 100 nM MCJ
siRNA using Jetprime reagent (Polyplus). Controls were transfected with an
unrelated siRNA (Qiagen). Protein knockdown was confirmed by western blotting.
Cell transfection. WT primary hepatocytes were transfected with 2 μg of pCMV6-
MCJ using jetPRIMETM reagent (Polyplus). pcDNA3-LacZ (Invitrogen) was used
as a negative control.
Drug treatments. APAP was dissolved in PBS and used at a dose of 10 mM
in vitro and 360 mg/kg in vivo. The complex I inhibitor Rotenone (Sigma-Aldrich)
was used at a dose of 0.1 μM and administered 3 h after APAP.
Protein isolation and western blotting. Total protein extracts from primary
hepatocytes and hepatic tissue were resolved in sodium dodecyl
sulfate–polyacrylamide gels and transferred to nitrocellulose membranes. The
antibodies used for western blotting are described in Supplementary Table 1. As a
loading control, we used GAPDH antibody (Abcam). As secondary antibodies, we
used anti-rabbit-IgG-HRP-linked (Cell Signaling) and anti-mouse IgG-HRP-linked
(Santa Cruz Biotechnology). All experiments were performed at least three times.
Uncropped scans of western blots are showed in Supplementary Fig. 6.
RNA isolation and quantitative real-time polymerase chain reaction. Total
RNA was isolated with Trizol (Invitrogen). About 1–2 μg of total RNA was treated
with DNAse (Invitrogen) and reverse transcribed into complimentary DNA using
M-MLV Reverse Transcriptase (Invitrogen). Quantitative real-time PCR (RT-PCR)
was performed using SYBR Select Master Mix (Applied Biosystems) and the Viia 7
Real-Time PCR System (Applied Biosystems). The Ct values were extrapolated to a
standard curve, and data were then normalized to the housekeeping expression
(GAPDH). Primers are described in Supplementary Table 2.
Mitochondria isolation. Mitochondrial fractions from primary hepatocytes and
hepatic tissue were obtained using the Mitochondrial/Cytosol Fractionation Kit
from Abcam (ab65320).
Respiration studies in hepatocytes and liver mitochondria. The respiration of
primary hepatocytes and liver mitochondria was measured at 37 °C by high-
resolution respirometry with the Seahorse Bioscience XF24-3 Extracellular Flux
Analyzer. For the measurement of the OCR, as the rate change of dissolved O2,
primary WT, and MCJ KO mouse hepatocytes were seeded, respectively, in a
collagen I-coated XF24 cell culture microplate (Seahorse Bioscience), at 2.0 × 104
cells per well. After 3 h, 100 μl of growth media was added. The day after, growth
medium was removed and replaced with 500 μl of assay medium prewarmed to 37 °
C, composed of DMEM without bicarbonate containing 1 mM sodium pyruvate, 2
mM L-glutamine, and cultured at 37 °C in room air. Measurements of OCR were
performed after equilibration in assay medium for 1 h. After an OCR baseline
measurement, sequential injections were performed through ports in the XF assay
cartridges. The following pharmacologic inhibitors were used: oligomycin (1 mM),
an inhibitor of ATP synthase, which allows the measurement of ATP-coupled
oxygen consumption through OXPHOS; carbonyl cyanide 4-trifluoromethoxy-
phenylhydrazone (FCCP) (300 nM), an uncoupling agent that allows maximum
electron transport, and therefore a measurement of the maximal OXPHOS
respiration capacity; and Rotenone (1 μM), a mitochondrial complex I inhibitor.
Upon the sequential delivery of the inhibitors, changes in OCR were recorded. For
the APAP experiments, APAP was injected first. For mitochondrial respiration
experiments, liver mitochondria were isolated as described3 and complex I
respiration measurements were made in the presence of glutamate (10 mM) and
malate (2 mM), followed by the addition of ADP (4 mM) (state 3 respiration).
APAP 10mM was injected and the inhibition ratio of complexes I by APAP was
determined. The production of ATP through complex I was calculated by the
addition of oligomycin (1 mM). The normalized data were expressed as pmol of O2
per minute or milli-pH units (mpH) per minute, per μg protein for primary
hepatocytes, and viability measured by MTT assay for isolated mitochondria.
Determination of mitochondrial ROS. Mitochondrial ROS production in primary
hepatocytes was assessed using MitoSOX Red mitochondrial superoxide indicator
(Invitrogen). The hepatocytes were loaded with 1.5 mM MitoSOX Red for 10 min
at 37 °C in a CO2 incubator. The hepatocytes were then carefully washed three
times with hot PBS. Fluorescence (510 nm excitation, 495 nm emission) was
monitored using a SpectraMax M2 plate reader (Molecular Devices, CA, USA). The
data were plotted as relative fluorescence units (RFU).
Intracellular ATP level determination. The levels of intracellular ATP in primary
hepatocytes or liver mitochondria were determined using the ATPlite luminescence
ATP detection assay system (PerkinElmer) by following the recommendations
from the manufacturer.
TUNEL assay. TUNEL assay was performed in frozen liver sections and primary
hepatocytes using the in situ cell death detection kit (Roche) according to the
manufacturer’s instructions.
Blue native PAGE. Purified mitochondria were solubilized in native PAGE loading
buffer (Invitrogen) containing 2% digitonin (Sigma). Complexes were resolved by
electrophoresis in 4–16% NativePAGE Novex Bis-Tris gels (Invitrogen) followed
by transfer to a polyvinylidene difluoride (PVDF) membrane for western blot
analysis.
Quantification of GSSG, GSH, and NAPQI–GSH levels. Liver extracts were
analyzed with a UPLC system (Acquity, Waters, Manchester) coupled to a Time of
Flight mass spectrometer (ToF MS, SYNAPT G2, Waters). A 2.1 × 100 mm, 1.7
mm BEH amide column (Waters), stabilized at 40 °C, was used to separate the
analytes before entering the MS. Solvent A (aqueous phase) consisted of 99.5%
water, 0.5% formic acid, and 20 mM ammonium formate while solvent B (organic
phase) consisted of 29.5% water, 70% MeCN, 0.5% formic acid, and 1 mM
ammonium formate. The extracted ion trace was obtained for GSH (m/z =
308.0916) and GSSG (m/z = 613.1598) and in the case of NAPQI–GSH (m/z=
457.139) in a 20 mDa window and subsequently smoothed (2 points, 2 iterations)
and integrated with QuanLynx software (Waters, Manchester).
Statistical analysis. Statistical significance was determined by two-way analysis of
variance followed by a Student’s t test.
Data availability. The data sets generated during and/or analyzed during the
current study are included in this published article (and its Supplementary
Information Files) or available from the corresponding authors on reasonable
request.
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